Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

Based on available data, most multiple myeloma patients have residual myeloma cells in their autologous hematopoietic progenitor cells (HPC) grafts during collection for autologous stemcell transplant. However, available literature is based on older induction regimens, e.g., adriamycin and dexametha...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Bone Marrow Transplant
Auteurs principaux: Tageja, Nishant, Korde, Neha, Kazandjian, Dickran, Manasanch, Elisabet, Bhutani, Manisha, Kwok, Mary, Mailankody, Sham, Yuan, Constance, Stetler-Stevenson, Maryalice, Leitman, Susan F., Sportes, Claude, Landgren, Ola
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6740327/
https://ncbi.nlm.nih.gov/pubmed/29728700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41409-018-0170-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires